CONCLUSION
Discontinuation of Imatinib in FIP1L1-PDGFRA-positive HES is currently
being evaluated. It is feasible, providing regular biological monitoring
of CHR and CMR to detect relapse. The rapid achievement of a second
remission is an additional incentive to stop the treatment.